Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 10, 25-34. doi:10.1016/S1470-2045(08)70285-7

has been cited by the following article:

• TITLE: Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar

  AUTHORS: Kakil Ibrahim Rasul

  KEYWORDS: Hepatocellular Ca; Sorafenib; Chemoembolization

  JOURNAL NAME: Modern Chemotherapy, Vol.1 No.1, July 23, 2012

  ABSTRACT: Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.